loading
Corcept Therapeutics Inc stock is traded at $70.33, with a volume of 866.15K. It is down -0.92% in the last 24 hours and up +1.81% over the past month. Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
See More
Previous Close:
$70.98
Open:
$71.17
24h Volume:
866.15K
Relative Volume:
0.72
Market Cap:
$7.41B
Revenue:
$628.56M
Net Income/Loss:
$141.82M
P/E Ratio:
55.82
EPS:
1.26
Net Cash Flow:
$142.60M
1W Performance:
-1.97%
1M Performance:
+1.81%
6M Performance:
+10.69%
1Y Performance:
+105.16%
1-Day Range:
Value
$69.73
$71.27
1-Week Range:
Value
$69.73
$72.33
52-Week Range:
Value
$33.34
$117.33

Corcept Therapeutics Inc Stock (CORT) Company Profile

Name
Name
Corcept Therapeutics Inc
Name
Phone
650.688.8803
Name
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Name
Employee
500
Name
Twitter
Name
Next Earnings Date
2025-02-17
Name
Latest SEC Filings
Name
CORT's Discussions on Twitter

Compare CORT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CORT
Corcept Therapeutics Inc
70.33 7.56B 628.56M 141.82M 142.60M 1.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-06-23 Upgrade Truist Hold → Buy
Apr-11-23 Initiated SVB Securities Market Perform
Apr-04-23 Initiated Piper Sandler Overweight
Feb-15-23 Downgrade Jefferies Buy → Hold
Aug-01-22 Downgrade Truist Buy → Hold
Jul-27-22 Upgrade Jefferies Hold → Buy
Jun-27-22 Resumed Canaccord Genuity Buy
Feb-02-22 Initiated Canaccord Genuity Buy
Jan-28-22 Initiated Truist Buy
Aug-05-20 Downgrade Jefferies Buy → Hold
Sep-24-19 Initiated Jefferies Buy
Sep-06-19 Initiated H.C. Wainwright Buy
Feb-04-19 Downgrade B. Riley FBR Buy → Neutral
Aug-10-18 Reiterated Stifel Hold
May-31-18 Downgrade Stifel Buy → Hold
Mar-09-18 Initiated B. Riley FBR, Inc. Buy
Aug-31-17 Initiated Stifel Buy
Feb-02-17 Initiated Ladenburg Thalmann Buy
Apr-21-15 Initiated FBR Capital Outperform
Jan-13-14 Downgrade Stifel Buy → Hold
Aug-09-13 Downgrade Janney Buy → Neutral
Aug-09-13 Downgrade Ladenburg Thalmann Buy → Neutral
Feb-21-12 Reiterated JMP Securities Mkt Outperform
Jan-06-10 Upgrade Ladenburg Thalmann Neutral → Buy
Jul-17-08 Initiated Rodman & Renshaw Mkt Outperform
Jun-21-07 Upgrade Punk, Ziegel & Co Mkt Perform → Accumulate
View All

Corcept Therapeutics Inc Stock (CORT) Latest News

pulisher
Aug 18, 2025

Is Corcept Therapeutics Incorporated a good ESG investmentJuly 2025 Intraday Action & High Return Trade Guides - classian.co.kr

Aug 18, 2025
pulisher
Aug 17, 2025

With 70% Institutional Ownership, Corcept Therapeutics Incorporated (NASDAQ:CORT) Is a Favorite Amongst the Big Guns - 富途牛牛

Aug 17, 2025
pulisher
Aug 17, 2025

What Technical Tools Say About Corcept Therapeutics Incorporated Recovery2025 Trading Volume Trends & Safe Capital Growth Stock Tips - metal.it

Aug 17, 2025
pulisher
Aug 15, 2025

Corcept Therapeutics Advances Liver Fat Reduction Study with Miricorilant - MSN

Aug 15, 2025
pulisher
Aug 14, 2025

Corcept Therapeutics: Buy Rating Backed by Promising Developments in Glucocorticoid Modulation and Oncology Expansion - TipRanks

Aug 14, 2025
pulisher
Aug 13, 2025

Watch for Bullish Crossover in Corcept Therapeutics IncorporatedJuly 2025 Closing Moves & Consistent Profit Focused Trading Strategies - beatles.ru

Aug 13, 2025
pulisher
Aug 13, 2025

CORT Q2 Deep Dive: Product Supply Constraints and Pipeline Progress Reshape Outlook - Yahoo Finance

Aug 13, 2025
pulisher
Aug 13, 2025

5 Must-Read Analyst Questions From Corcept’s Q2 Earnings Call - Yahoo Finance

Aug 13, 2025
pulisher
Aug 13, 2025

Corcept Therapeutics Insider Sold Shares Worth $2,512,452, According to a Recent SEC Filing - MarketScreener

Aug 13, 2025
pulisher
Aug 12, 2025

Corcept therapeutics director Swisher sells $159k in shares By Investing.com - Investing.com Nigeria

Aug 12, 2025
pulisher
Aug 12, 2025

Corcept therapeutics officer sells $2.5M in shares By Investing.com - Investing.com Australia

Aug 12, 2025
pulisher
Aug 12, 2025

Corcept therapeutics director Swisher sells $159k in shares - Investing.com

Aug 12, 2025
pulisher
Aug 12, 2025

Corcept therapeutics officer sells $2.5M in shares - Investing.com

Aug 12, 2025
pulisher
Aug 12, 2025

Corcept Therapeutics Announces CDO William Guyer's Share Buy and Sell Transactions - AInvest

Aug 12, 2025
pulisher
Aug 07, 2025

Corcept Therapeutics: Pioneering a $2.8B Market in Type 2 Diabetes via Hypercortisolism Treatment - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Corcept's Q2 Demand Grows 60% Penetrating Large Type 2 Diabetes Market Early (NASDAQ:CORT) - Seeking Alpha

Aug 07, 2025
pulisher
Aug 07, 2025

Corcept Therapeutics’ MOMENTUM Study: Assessing Hypercortisolism in Resistant Hypertension - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

Corcept Therapeutics Advances in Ovarian Cancer Treatment with New Phase 2 Study - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

Why Corcept Therapeutics' (NASDAQ:CORT) Earnings Are Better Than They Seem - Yahoo Finance

Aug 07, 2025
pulisher
Aug 06, 2025

Assessing the Impact of Pre-Scheduled Insider Sales at Corcept Therapeutics on Investor Confidence and Market Dynamics - AInvest

Aug 06, 2025
pulisher
Aug 06, 2025

Corcept Therapeutics Insider Sold Shares Worth $2,373,237, According to a Recent SEC Filing - MarketScreener

Aug 06, 2025
pulisher
Aug 06, 2025

Corcept Therapeutics Insider Sold Shares Worth $393,128, According to a Recent SEC Filing - MarketScreener

Aug 06, 2025
pulisher
Aug 05, 2025

Corcept therapeutics officer Lyon sells $393k in shares By Investing.com - Investing.com Nigeria

Aug 05, 2025
pulisher
Aug 05, 2025

Corcept therapeutics (CORT) CEO Belanoff sells $2.74 million in stock By Investing.com - Investing.com India

Aug 05, 2025
pulisher
Aug 05, 2025

Corcept therapeutics (CORT) CEO Belanoff sells $2.74 million in stock - Investing.com

Aug 05, 2025
pulisher
Aug 04, 2025

Cushings Syndrome Market Exclusive Report with Detailed Study - openPR.com

Aug 04, 2025
pulisher
Aug 03, 2025

How does Corcept Therapeutics Incorporated compare to its industry peersLightning-fast growth - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How strong is Corcept Therapeutics Incorporated company’s balance sheetTriple-digit wealth increases - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How volatile is Corcept Therapeutics Incorporated stock compared to the marketGet professional advice for market timing - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Corcept Therapeutics Analyst Rating Update: Canaccord Genuity Maintains 'Buy' Rating with Lowered Price Target to 137.00 USD - AInvest

Aug 03, 2025
pulisher
Aug 03, 2025

What catalysts could drive Corcept Therapeutics Incorporated stock higher in 2025Dynamic profit opportunities - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Why is Corcept Therapeutics Incorporated stock attracting strong analyst attentionFastest return on investment - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are the latest earnings results for Corcept Therapeutics IncorporatedInvest smarter with daily stock recommendations - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What analysts say about Corcept Therapeutics Incorporated stockRealize exceptional returns through smart trading - Jammu Links News

Aug 03, 2025
pulisher
Aug 02, 2025

CORT's Q2 Earnings Beat and Pipeline Momentum: A Case for Revisiting the Downside as a Buy Opportunity - AInvest

Aug 02, 2025
pulisher
Aug 02, 2025

When is Corcept Therapeutics Incorporated stock expected to show significant growthTremendous financial leverage - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

Corcept Therapeutics (CORT): A High-Conviction Buy Amidst Breakthroughs in Cortisol-Modulating Therapies - AInvest

Aug 02, 2025
pulisher
Aug 02, 2025

Corcept Therapeutics Incorporated (NASDAQ:CORT) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 02, 2025
pulisher
Aug 02, 2025

Corcept Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Aug 02, 2025
pulisher
Aug 01, 2025

Published on: 2025-08-02 05:25:16 - metal.it

Aug 01, 2025
pulisher
Aug 01, 2025

Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates - MSN

Aug 01, 2025
pulisher
Aug 01, 2025

Corcept Therapeutics’ Earnings Call: Growth Amid Challenges - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

Corcept Therapeutics Incorporated Recovery Hinges on Volume BreakoutNews Based Entry Opportunity Alerts Detected - metal.it

Aug 01, 2025
pulisher
Aug 01, 2025

Corcept Faces Growing Pains As Earnings Miss The Mark - Finimize

Aug 01, 2025
pulisher
Aug 01, 2025

Corcept Therapeutics Reports Q2 2025 Financial Results - The Globe and Mail

Aug 01, 2025
pulisher
Aug 01, 2025

CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down - Yahoo Finance

Aug 01, 2025
pulisher
Aug 01, 2025

A Quick Look at Today's Ratings for Corcept Therapeutics(CORT.US), With a Forecast Between $121 to $145 - 富途牛牛

Aug 01, 2025
pulisher
Aug 01, 2025

Corcept Therapeutics 2025 Q2 Earnings Misses Targets as Net Income Declines 1% - AInvest

Aug 01, 2025
pulisher
Aug 01, 2025

Corcept Therapeutics Q2 CY2025: Revenue Misses, Earnings BeatNews and Statistics - IndexBox

Aug 01, 2025
pulisher
Aug 01, 2025

Corcept Therapeutics shares fall 3.38% premarket after Q2 revenue misses estimates. - AInvest

Aug 01, 2025
pulisher
Aug 01, 2025

Corcept: Q2 Earnings Snapshot - Connecticut Post

Aug 01, 2025

Corcept Therapeutics Inc Stock (CORT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Corcept Therapeutics Inc Stock (CORT) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Swisher Daniel N JR
Director
Aug 11 '25
Sale
72.30
2,200
159,060
0
Guyer William
Chief Development Officer
Aug 08 '25
Option Exercise
21.65
35,007
757,902
40,494
Guyer William
Chief Development Officer
Aug 08 '25
Sale
71.77
35,007
2,512,452
5,487
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):